1、平稳降压 肾脏保护,内 容,CCB慢性肾病的优质选择乐卡地平平稳降压 保护血管,肾病合并高血压的患者比例意大利门诊肾病患者预测,Clin J Am Soc Nephrol. 2011 October; 6(10): 24212428,Prevalence of chronic kidney disease in China:a cross-sectional survey,50550 人参与此次调查, 47204人完成调查；1.7%的人eGFR 60 mL/min/1.73 m2 (95% CI 1.51.9) ，蛋白尿的发生率 9.4% ；中国慢性肾病发病率10.8% ，中国估计有CKD 患
2、者1.2亿 (112.9125.0 million)；农村地区与经济发展和蛋白尿的发生独立相关。,Lancet 2012; 379: 815822,Hypertension Awareness, Treatment, and Control in Adults With CKD:CRIC study,%,Am J Kidney Dis. 2010 March ; 55(3): 441451,SBP130 mm HG (40%),Am J Kidney Dis. 2010 March ; 55(3): 441451,DBP80 mm HG (72%),%,Hypertension Awarene
3、ss, Treatment, and Control in Adults With CKD:CRIC study,Number of blood pressure medications being taken by participants in CRIC study,Am J Kidney Dis. 2010 March ; 55(3): 441451,Blood pressure control in the CRIC study,1,2,3,4,Number of anti-hypertensive medications,Controled %,SBP/DBP140/90mmHg,SBP/DBP 500 mg/day) 患者68例(年龄 63.1 12.9 岁, 男性69.1% ，女性30.9 %)；所有患者均接受过ACEI(51.4%) 或 ARB (48.6%)治疗，但血压并没有达到尿蛋白患者推荐的目标值(130/80 mmHg)；患者接受乐卡地平20mg/天治疗后分别经历了1个月，3个月和6个月三次评估随访； 肌酐清除率通过 24h尿量收集测定。,Renal Failure, 32:192197, 2010,乐卡地平增强RASI保护肾脏功能,尿蛋白降低（%）,Renal Failure, 32:192197, 2010,感谢您的关注！,
